Common Stock, par value $0.007 per share
- Symbol
- BIAF
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
bioAffinity Technologies, Inc.
BIAFNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On July 27, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing the publication of a comprehensive clinical review and white paper authored by the Company’s Chief Medical Officer, Gordon H.…
Company context
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Current securities
Registered securities in this filing
bioAffinity Technologies, Inc. · 8-K · Filed 2026-07-27
Warrants to purchase Common Stock
- Symbol
- BIAFW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01. Other Events.
On
July 27, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing
the publication of a comprehensive clinical review and white paper authored by the Company’s Chief Medical Officer, Gordon H. Downie,
MD, PhD, that presents a practical clinical framework for incorporating CyPath ® Lung into pulmonary nodule evaluation
and cancer surveillance.
A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
As
of July 24, 2026, there were 7,783,061 outstanding shares of the Company’s common stock and the aggregate market value of the Company’s
common stock was approximately $5.1 million based on the closing price of a share of the Company’s common stock on that date, as
reported by the Nasdaq Capital Market.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung Comprehensive clinical review outlines specialty-specific approaches for integrating the test’s lung microenvironment analysis into diagnostic pathway Framework includes protocols for pulmonology, primary care and oncology practices for detection of lung cancer and surveillance of survivors SAN ANTONIO, TX - July 27, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the publication of a comprehensive clinical review and white paper authored by Chief Medical Officer Gordon H. Downie, MD, PhD, that presents a practical clinical framework for incorporating CyPath® Lung into pulmonary nodule evaluation and cancer surveillance. Titled “ Lung Nodules, Lung Microenvironment, Predictive Models and Clinician Risk Stratification Using CyPath® Lung Testing for Early Diagnosis of Lung Cancer,” the paper examines the growing clinical challenge of evaluating pu…
Open exhibit ↗